Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelofibrosis，MF”

141 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 141 results

Testing effectiveness (Phase 2)Ended earlyNCT02431260
What this trial is testing

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Who this might be right for
Solid Tumors and Hematologic Malignancy
Incyte Corporation 69
Post-approval studies (Phase 4)Active Not RecruitingNCT02386800
What this trial is testing

CINC424A2X01B Rollover Protocol

Who this might be right for
Primary MyelofibrosisPolycythemia VeraGraft Versus Host Disease+2 more
Novartis Pharmaceuticals 279
Early research (Phase 1)Active Not RecruitingNCT04454658
What this trial is testing

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Who this might be right for
Myelofibrosis (MF)
AbbVie 21
Early research (Phase 1)Looking for participantsNCT07302776
What this trial is testing

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Who this might be right for
GVHDHematopoietic Cell Transplantation (HCT)Acute Myeloid Leukemia (AML)+4 more
Stanford University 50
Not applicableNot Yet RecruitingNCT07440654
What this trial is testing

Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis

Who this might be right for
aGVHD Prophylaxis
Nanfang Hospital, Southern Medical University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574
What this trial is testing

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more
Chengdu Zenitar Biomedical Technology Co., Ltd 105
Testing effectiveness (Phase 2)Temporarily pausedNCT01211691
What this trial is testing

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Who this might be right for
Myelodysplastic Syndrome (MDS)Myelofibrosis (MF)
Humanigen, Inc. 120
Early research (Phase 1)Not Yet RecruitingNCT07529951
What this trial is testing

Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

Who this might be right for
Polycythemia Vera (PV)Myelofibrosis (MF)
Eilean Therapeutics 60
Testing effectiveness (Phase 2)Study completedNCT02420873
What this trial is testing

An Open-label Phase II Study of Lorvotuzumab Mertansine

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 9
Large-scale testing (Phase 3)UnknownNCT03662126
What this trial is testing

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)
Kartos Therapeutics, Inc. 385
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07471503
What this trial is testing

Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis

Who this might be right for
Myelofibrosis (MF)HSCT
Institute of Hematology & Blood Diseases Hospital, China 39
Not applicableStudy completedNCT00715247
What this trial is testing

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Who this might be right for
Polycythemia VeraEssential ThrombocythemiaMyelofibrosis
University of Utah 726
Large-scale testing (Phase 3)Ended earlyNCT04551066
What this trial is testing

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 252
Testing effectiveness (Phase 2)UnknownNCT04640532
What this trial is testing

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+1 more
Kartos Therapeutics, Inc. 116
Early research (Phase 1)WithdrawnNCT04283526
What this trial is testing

Study of Select Combinations in Adults With Myelofibrosis

Who this might be right for
Primary MyelofibrosisMyelofibrosisPMF+2 more
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT02493530
What this trial is testing

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Who this might be right for
MyelofibrosisPolycythemia Vera
Vanderbilt-Ingram Cancer Center 60
Early research (Phase 1)Study completedNCT01317875
What this trial is testing

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Who this might be right for
Myelofibrosis
Incyte Corporation 69
Early research (Phase 1)Study completedNCT01433445
What this trial is testing

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Who this might be right for
Idiopathic MyelofibrosisPost Essential Thrombocythemia MyelofibrosisPost Polycythemia-Vera Myelofibrosis
Novartis Pharmaceuticals 61
Early research (Phase 1)Ended earlyNCT01730248
What this trial is testing

Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 63
Large-scale testing (Phase 3)Looking for participantsNCT06479135
What this trial is testing

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+2 more
Kartos Therapeutics, Inc. 600
Next Page